US FDA inspection at Pithampur facility - 2 procedural observations

Regulatory & Legal View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹1312.10

prior close

₹1330.50

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%+3.4% vs market

Pharmaceuticals peers, median of 164sector-0.5%+4.1% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+2.1

15m

+3.2

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.2+3.4-0.5+4.1

Next day

+5.5-0.5+6.0-0.7+6.2

+6.8-2.5+9.4-1.7+8.5

+7.3-0.6+7.9-1.3+8.6

+9.0+0.7+8.3-0.5+9.5

+9.7+0.9+8.9+0.2+9.5

+10.6+0.5+10.1+0.4+10.1

15d

+20.0-0.2+20.2-1.4+21.4

+17.0+2.9+14.1-1.7+18.7

+33.5+5.0+28.6+1.2+32.3

+21.5+3.7+17.8+0.4+21.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA conducted an unannounced inspection of Rubicon Research's Pithampur (Madhya Pradesh) manufacturing facility from June 29 to July 3, 2026. This was the first FDA inspection since the facility was acquired last year. A Form 483 was issued with 2 procedural observations, none related to data integrity. The company plans to respond timely and expects commercial operations to ramp up from Q1 CY2027.

Likely market impact

Minor procedural observations, no data integrity issues. Positive outcome expected; supports commercial ramp-up from Q1 CY2027.